Integra LifeSciences Holdings Corporation (IART) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Diluted Earnings Per Share | 0.54 USD_per_share | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 76.18M | FY2026-Q1 |
| Codman Specialty Surgical Revenue | 283.1M | FY2026-Q1 |
| Adjusted Gross Margin | 64.10 percent | FY2026-Q1 |
| Adjusted Net Income | 41.6M | FY2026-Q1 |
| Total Organic Revenue | 387.47M | FY2026-Q1 |
| Instruments Revenue | 47.23M | FY2026-Q1 |
| Neurosurgery Revenue | 198.2M | FY2026-Q1 |
| Private Label Revenue | 29.14M | FY2026-Q1 |
| Ear Nose and Throat Revenue | 37.71M | FY2026-Q1 |
| Tissue Technologies Revenue | 111.6M | FY2025-Q4 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization Margin | 24.00 percent | FY2025-Q4 |
| Wound Reconstruction and Care Revenue | 83.99M | FY2025-Q3 |
Back to IART overview · IART earnings · IART holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.